<PAPER>
  <mode2 name="16777995_arathi" hasDoc="yes" version="1258"/>
  <TITLE>
    <s sid="1">Genistein and quercetin increase connexin43 and suppress growth of breast cancer cells<CoreSc1 atype="GSC" type="Res" conceptID="Res1" novelty="None" advantage="None"/></s>
  </TITLE>
  <ABSTRACT>
    <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-1">
      <s sid="2">Connexin proteins form gap junctions, which permit direct exchange of cytoplasmic contents between neighboring cells.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac1" novelty="None" advantage="None"/></s>
      <s sid="3">Evidence indicates that gap junctional intercellular communication (GJIC) is important for maintaining homeostasis and preventing cell transformation.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac2" novelty="None" advantage="None"/></s>
      <s sid="4">Furthermore, connexins may have independent functions including tumor growth suppression.<CoreSc1 atype="GSC" type="Hyp" conceptID="Hyp1" novelty="None" advantage="None"/></s>
      <s sid="5">Most tumors express less connexins, have reduced GJIC and have increased growth rates compared with non-tumorigenic cells.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac3" novelty="None" advantage="None"/></s>
      <s sid="6">The purpose of this study was to determine whether common flavonoids, genistein and quercetin, increase connexin43 (Cx43) levels, improve GJIC and suppress growth of a metastatic human breast tumor cell line (MDA-MB-231).<CoreSc1 atype="GSC" type="Goa" conceptID="Goa1" novelty="None" advantage="None"/></s>
      <s sid="7">Quercetin (2.5, 5 &#956;g/ml) and genistein (0.5, 2.5, 15 &#956;g/ml) upregulated Cx43 but failed to increase GJIC.<CoreSc1 atype="GSC" type="Res" conceptID="Res2" novelty="None" advantage="None"/></s>
      <s sid="8">Cx43 localized to the plasma membrane following genistein treatment (2.5, 15 &#956;g/ml).<CoreSc1 atype="GSC" type="Obs" conceptID="Obs1" novelty="None" advantage="None"/></s>
      <s sid="9">In contrast, Cx43 aggregated in the perinuclear region following quercetin treatment (0.5, 2.5, 5, 15 &#956;g/ml).<CoreSc1 atype="GSC" type="Obs" conceptID="Obs2" novelty="None" advantage="None"/></s>
      <s sid="10">Both genistein (15 &#956;g/ml) and quercetin (2.5, 5, 15 &#956;g/ml) significantly reduced MDA-MB-231 cell proliferation.<CoreSc1 atype="GSC" type="Res" conceptID="Res3" novelty="None" advantage="None"/></s>
      <s sid="11">In summary, genistein and quercetin increase Cx43 and suppress MDA-MB-231 cell proliferation at physiologically relevant concentrations.<CoreSc1 atype="GSC" type="Res" conceptID="Res4" novelty="None" advantage="None"/></s>
      <s sid="12">These results demonstrate that genistein and quercetin are potential anti-breast cancer agents.<CoreSc1 atype="GSC" type="Con" conceptID="Con1" novelty="None" advantage="None"/></s>
    </p>
  </ABSTRACT>
  <BODY>
    <SEC>
      <TITLE>Introduction</TITLE>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-2">
        <s sid="13">Breast tumors are the most common type of cancer in Caucasian women living in Western nations (<xref class="xref-bibr" href="#ref-1" rid="xref-ref-1-1">1</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac4" novelty="None" advantage="None"/></s>
        <s sid="14">It is estimated that &#8764;1 in 8 North American females will develop breast cancer throughout their lifetime, and 1 in 30 will die from the disease.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac5" novelty="None" advantage="None"/></s>
        <s sid="15">Many traditional treatments, include hormone therapy, radiation therapy, chemotherapy and surgical tumor removal, do not ensure a cure and are associated with significant physiological and psychological side effects (<xref class="xref-bibr" href="#ref-2" rid="xref-ref-2-1">2</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac6" novelty="None" advantage="None"/></s>
        <s sid="16">Therefore, there is a need for more effective treatments with minimal side effects.<CoreSc1 atype="GSC" type="Mot" conceptID="Mot1" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-3">
        <s sid="17">Experimental and clinical evidence indicates that cancer is a multi-step process reflecting genetic alterations, which drive the progressive transformation of normal cells to highly malignant ones.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac7" novelty="None" advantage="None"/></s>
        <s sid="18">Malignant tumors are characterized by self-sufficient growth, insensitivity to anti-growth signals, sustained angiogenesis, the ability to evade apoptosis, replicate indefinitely, and invade surrounding tissue and spread to distant organs.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac8" novelty="None" advantage="None"/></s>
        <s sid="19">Cell autonomy and dysregulated homeostasis are central to many of these malignant characteristics (<xref class="xref-bibr" href="#ref-3" rid="xref-ref-3-1">3</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac9" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-4">
        <s sid="20">Adjacent cells are able to exchange potential homeostatic regulators, including possible anti-growth signals and apoptotic factors, through hydrophilic channels called gap junctions.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac10" novelty="None" advantage="None"/></s>
        <s sid="21">Each gap junction channel is formed by two hemichannels (connexons) embedded in the plasma membrane of adjacent cells.<CoreSc1 atype="GSC" type="Obj" conceptID="Obj1" novelty="None" advantage="None"/></s>
        <s sid="22">Each hemichannel is in turn composed of six connexin proteins (<xref class="xref-bibr" href="#ref-4" rid="xref-ref-4-1">4</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac11" novelty="None" advantage="None"/></s>
        <s sid="23">Presently, 21 different human connexin genes have been identified (<xref class="xref-bibr" href="#ref-5" rid="xref-ref-5-1">5</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac12" novelty="None" advantage="None"/></s>
        <s sid="24">Three connexin proteins have been identified in human breast tissue: Cx43, Cx26 and Cx32 (<xref class="xref-bibr" href="#ref-6" rid="xref-ref-6-1">6</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac13" novelty="None" advantage="None"/></s>
        <s sid="25">Cx43 is the most common connexin protein in breast tissue, and is most prominent in basal and lateral surfaces of myoepithelial cells.<CoreSc1 atype="GSC" type="Obj" conceptID="Obj2" novelty="None" advantage="None"/></s>
        <s sid="26">Cx26 has been identified between luminal cells in major ducts, and to a lesser extent in alveolar/lobular structures and in breast epithelium.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac14" novelty="None" advantage="None"/></s>
        <s sid="27">Cx32 has been identified in mammary glands in the secretory luminal cells of alveoli during lactation and has been observed co-localized with Cx26 in non-pregnant human breast tissue (<xref class="xref-bibr" href="#ref-6" rid="xref-ref-6-2">6</xref>,<xref class="xref-bibr" href="#ref-7" rid="xref-ref-7-1">7</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac15" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-5">
        <s sid="28">Most tumors exhibit dysfunctional gap junctional intercellular communication (GJIC) and decreased Cx43 expression (<xref class="xref-bibr" href="#ref-8" rid="xref-ref-8-1">8</xref>,<xref class="xref-bibr" href="#ref-9" rid="xref-ref-9-1">9</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac16" novelty="None" advantage="None"/></s>
        <s sid="29">Additionally, connexin proteins may be internalized and degraded by lysosomes and proteosomes, or impeded during transport to the plasma membrane (<xref class="xref-bibr" href="#ref-10" rid="xref-ref-10-1">10</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac17" novelty="None" advantage="None"/></s>
        <s sid="30">Alternatively, tumor promoters such as 12-O-tetradecanoyl phorbol-13-acetate (TPA) or excessive connexin phosphorylation can block the exchange of possible homeostatic regulators through gap junction pores (<xref class="xref-bibr" href="#ref-11" rid="xref-ref-11-1">11</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac18" novelty="None" advantage="None"/></s>
        <s sid="31">However, studies have shown that flavonoids, plant-derived molecules with estrogenic activity, can maintain GJIC, and suppress tumor growth, in the presence of tumor promoters (<xref class="xref-bibr" href="#ref-12" rid="xref-ref-12-1">12</xref>&#8211;<xref class="xref-bibr" href="#ref-14" rid="xref-ref-14-1">14</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac19" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-6">
        <s sid="32">Connexin proteins have also been shown to have antitumor effects independent of channel function.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac20" novelty="None" advantage="None"/></s>
        <s sid="33">Transfection of Cx43 into human glioblastoma cells significantly reduced cell proliferation in monolayer culture and in nude mice without increasing GJIC (<xref class="xref-bibr" href="#ref-15" rid="xref-ref-15-1">15</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac21" novelty="None" advantage="None"/></s>
        <s sid="34">Also, the C-terminal region of Cx43 protein has been shown to reduce levels of S phase kinase associated protein 2 (Spk2), which in turn suppresses degradation of p27, a protein which halts the cell cycle between the G<sub>1</sub> and S phases (<xref class="xref-bibr" href="#ref-16" rid="xref-ref-16-1">16</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac22" novelty="None" advantage="None"/></s>
        <s sid="35">Furthermore, introduction of Cx26 and Cx43 into various human breast cancer cell lines (MDA-MB-231, Hs578T and HBL100) suppressed growth independent of GJIC.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac23" novelty="None" advantage="None"/></s>
        <s sid="36">It was found that Cx43 protein reduced fibroblastic growth factor receptor (FGFR) expression and possibly affected the expression of other proteins involved in tumor progression (<xref class="xref-bibr" href="#ref-17" rid="xref-ref-17-1">17</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac24" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-7">
        <s sid="37">Asian females are 4&#8211;6 times less likely to develop breast cancer compared with North American females (<xref class="xref-bibr" href="#ref-18" rid="xref-ref-18-1">18</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac25" novelty="None" advantage="None"/></s>
        <s sid="38">However, when Asian females migrate to North America and adopt an American diet, their breast cancer incidence approaches that of North American women (<xref class="xref-bibr" href="#ref-19" rid="xref-ref-19-1">19</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac26" novelty="None" advantage="None"/></s>
        <s sid="39">This suggests that diet plays a significant role in breast cancer acquisition.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac27" novelty="None" advantage="None"/></s>
        <s sid="40">Asians consume a greater quantity of soy, fruit and vegetables compared with North Americans (<xref class="xref-bibr" href="#ref-20" rid="xref-ref-20-1">20</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac28" novelty="None" advantage="None"/></s>
        <s sid="41">These products are rich in flavonoids (<xref class="xref-bibr" href="#ref-21" rid="xref-ref-21-1">21</xref>,<xref class="xref-bibr" href="#ref-22" rid="xref-ref-22-1">22</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac29" novelty="None" advantage="None"/></s>
        <s sid="42">Research has shown that flavonoids have vasodilatory, antiviral, antioxidant, antiallergenic and antitumor functions (<xref class="xref-bibr" href="#ref-23" rid="xref-ref-23-1">23</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac30" novelty="None" advantage="None"/></s>
        <s sid="43">The most studied flavonoids with respect to antitumor functions are genistein and quercetin, which have been shown to have potent anti-proliferative effects on tumor cells by inducing apoptosis, halting the cell cycle, reducing the growth stimulatory effect of IP<sub>3</sub> and inhibiting tyrosine kinase activity (<xref class="xref-bibr" href="#ref-24" rid="xref-ref-24-1">24</xref>&#8211;<xref class="xref-bibr" href="#ref-27" rid="xref-ref-27-1">27</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac31" novelty="None" advantage="None"/></s>
        <s sid="44">Genistein and quercetin can also enhance differentiation, and inhibit estrogen effects by competitively binding to estrogen receptors (ERs) (<xref class="xref-bibr" href="#ref-28" rid="xref-ref-28-1">28</xref>,<xref class="xref-bibr" href="#ref-29" rid="xref-ref-29-1">29</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac32" novelty="None" advantage="None"/></s>
        <s sid="45">Additionally, flavonoids have been reported to upregulate connexin expression and increase GJIC in rat liver epithelial cells (<xref class="xref-bibr" href="#ref-30" rid="xref-ref-30-1">30</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac33" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-8">
        <s sid="46">This study investigated the growth suppressive effects of genistein and quercetin on a human metastatic breast tumor cell line, MDA-MB-231, through gap junctional mechanisms.<CoreSc1 atype="GSC" type="Obj" conceptID="Obj3" novelty="None" advantage="None"/></s>
        <s sid="47">The results demonstrate that genistein and quercetin are potential anti-breast cancer agents since they increased Cx43 expression at physiologically relevant concentrations and suppressed MDA-MB-231 cell proliferation at concentrations which were not toxic to either non-tumorigenic (MSTV1-7 cells) or metastatic human breast cells.<CoreSc1 atype="GSC" type="Res" conceptID="Res5" novelty="None" advantage="None"/></s>
      </p>
    </SEC>
    <SEC>
      <TITLE>Methods</TITLE>
      <h3 xmlns:xhtml="http://www.w3.org/1999/xhtml">Treatment chemicals</h3>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-9">
        <s sid="48">The flavonoids, genistein (98% HPLC from soybean) and quercetin (98% HPLC) were purchased from Sigma-Aldrich (St Louis, MO).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp1" novelty="None" advantage="None"/></s>
        <s sid="49">The flavonoids were dissolved in dimethyl sulfoxide (DMSO; Sigma-Aldrich) to 15 mg/ml, shielded from light and stored at &#8722;20&#176;C.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp2" novelty="None" advantage="None"/></s>
        <s sid="50">In all experiments, cells were treated with genistein (0.5, 2.5, 15 &#956;g/ml) or quercetin (0.5, 2.5, 5, 15 &#956;g/ml) in complete medium for 72 h.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp3" novelty="None" advantage="None"/></s>
        <s sid="51">The medium was replaced every 24 h during this treatment period.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp4" novelty="None" advantage="None"/></s>
        <s sid="52">Treatment controls consisted of complete medium only and vehicle control [complete medium supplemented with 0.1% (v/v) DMSO].<CoreSc1 atype="GSC" type="Exp" conceptID="Exp5" novelty="None" advantage="None"/></s>
      </p>
      <h3 xmlns:xhtml="http://www.w3.org/1999/xhtml">Cell culture</h3>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-10">
        <s sid="53">The non-tumorigenic human breast cell line MSTV1-7 was used as a positive control for Cx43 expression and GJIC.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp6" novelty="None" advantage="None"/></s>
        <s sid="54">MSTV1-7 cells were also used to determine whether genistein and/or quercetin treatments were toxic to non-tumorigenic breast cells.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp7" novelty="None" advantage="None"/></s>
        <s sid="55">Hs578T cells are a human breast tumor cell line, which express abundant Cx43 and readily communicate through gap junctions.<CoreSc1 atype="GSC" type="Obj" conceptID="Obj4" novelty="None" advantage="None"/></s>
        <s sid="56">Hs578T cells were used as a positive control for Cx43 immunoblotting and GJIC.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp8" novelty="None" advantage="None"/></s>
        <s sid="57">Experiments were performed on a metastatic human breast tumor cell line, MDA-MB-231.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp9" novelty="None" advantage="None"/></s>
        <s sid="58">All cell lines were obtained from American Type Culture Collection (Manassas, VA).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp10" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-11">
        <s sid="59">MSTV1-7 cells were grown in Dulbecco's modified Eagle's Nutrient Mixture F-12 Ham medium (Sigma-Aldrich) supplemented with 5% (v/v) fetal bovine serum (Invitrogen, Carlsbad, CA), 1% (v/v) <span class="sc">l</span>-glutamine (Invitrogen), 0.1% (v/v) penicillin&#8211;streptomycin (Invitrogen) and 0.1% (v/v) insulin (Invitrogen).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp11" novelty="None" advantage="None"/></s>
        <s sid="60">MDA-MB-231 cells were grown in RPMI 1640 medium (Sigma-Aldrich) supplemented with 10% (v/v) fetal bovine serum, 1% (v/v) <span class="sc">l</span>-glutamine and 0.1% (v/v) penicillin&#8211;streptomycin.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp12" novelty="None" advantage="None"/></s>
        <s sid="61">Hs578T cells were grown in Dulbecco's modified Eagle's medium (Sigma-Aldrich) supplemented with 10% (v/v) fetal bovine serum, 2% (v/v) <span class="sc">l</span>-glutamine and 0.1% (v/v) penicillin&#8211;streptomycin.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp13" novelty="None" advantage="None"/></s>
        <s sid="62">Cells were maintained at 37&#176;C in a humidified incubator containing 5% carbon dioxide.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp14" novelty="None" advantage="None"/></s>
      </p>
      <h3 xmlns:xhtml="http://www.w3.org/1999/xhtml">Cx43 immunocytochemistry</h3>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-12">
        <s sid="63">Cells were grown to confluence on 12 mm coverslips (Fischer Scientific; Hampton, NH) in 35 mm plates.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp15" novelty="None" advantage="None"/></s>
        <s sid="64">Following treatment, the cells were fixed with 80% methanol at &#8722;20&#176;C for 20 min.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp16" novelty="None" advantage="None"/></s>
        <s sid="65">Non-specific antibody binding was blocked with 10% (v/v) normal goat serum and 1% (w/v) bovine serum albumin (BSA) in phosphate-buffered saline (PBS).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp17" novelty="None" advantage="None"/></s>
        <s sid="66">The cells were then incubated with goat anti-rabbit Cx43 antibody (1:400 dilution; Sigma-Aldrich) in PBS with 1% (w/v) BSA for 1 h at room temperature.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp18" novelty="None" advantage="None"/></s>
        <s sid="67">Following washes with PBS, cells were incubated with Alexa-Fluor 568 goat anti-rabbit IgG secondary antibody (1:500 dilution; Molecular Probes, Eugene, OR) in PBS with 1% (w/v) BSA for 1 h at room temperature.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp19" novelty="None" advantage="None"/></s>
        <s sid="68">Cells were then washed with PBS, quickly rinsed with distilled, deionized water and then mounted with Vectashield medium (Vector Laboratories, Burlingame, CA).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp20" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-13">
        <s sid="69">Controls for immunocytochemistry consisted of PBS incubation in place of Cx43 primary and secondary antibody, affinity purified rabbit IgG in place of the Cx43 primary antibody and PBS in place of secondary antibody.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp21" novelty="None" advantage="None"/></s>
        <s sid="70">Fluorescent immunoreaction was visualized with a Zeiss Axiophot photomicroscope (Carl Zeiss, Thornwood, NY) equipped with filters for fluorescein isothiocyanate (FITC) (excitation 470 nm/emission 525 nm) and Alexa 568 (excitation 546 nm/emission 590 nm).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp22" novelty="None" advantage="None"/></s>
        <s sid="71">Differential interference contrast (DIC) and fluorescent images were viewed using the &#215;40 objective (oil).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp23" novelty="None" advantage="None"/></s>
        <s sid="72">Fluorescent images were captured at an exposure of 490 ms using Zeiss Axioplan 4 software (Carl Zeiss).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp24" novelty="None" advantage="None"/></s>
      </p>
      <h3 xmlns:xhtml="http://www.w3.org/1999/xhtml">Cx43, Ki67, DAPI immunocytochemistry</h3>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-14">
        <s sid="73">Ki67 (a proliferation marker), Cx43 and 4&#8242;-6-diamidine-2-phenylindole (DAPI) were combined in immunocytochemistry to test for the growth suppressive effects of genistein and quercetin and to quantify the proliferative activity in Cx43-expressing cells.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp25" novelty="None" advantage="None"/></s>
        <s sid="74">The same procedure as mentioned above for Cx43 immunocytochemistry was performed with the following alterations.<CoreSc1 atype="GSC" type="Met" conceptID="Met1" novelty="None" advantage="None"/></s>
        <s sid="75">Primary antibody incubation consisted of mouse anti-human Ki67 antibody (1:500 dilution; Sigma-Aldrich) combined with rabbit anti-human Cx43 antibody (1:400 dilution; Sigma-Aldrich).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp26" novelty="None" advantage="None"/></s>
        <s sid="76">Secondary antibody incubation consisted of Alexa-Fluor 568 goat anti-rabbit IgG (1:500; Molecular Probes) for Cx43 and Alexa-Fluor 488 goat anti-mouse IgG (1:500; Molecular Probes) for Ki67.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp27" novelty="None" advantage="None"/></s>
        <s sid="77">Cells were incubated for 5 min with DAPI (1:34&#8201;000; Molecular Probes) before mounting the coverslips.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp28" novelty="None" advantage="None"/></s>
        <s sid="78">The same immunocytochemistry controls were used as for Cx43 immunocytochemistry except that mouse IgG was used to control for the primary Ki67 antibody.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp29" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-15">
        <s sid="79">Ki67 staining was scored as positive or negative (<xref class="xref-bibr" href="#ref-31" rid="xref-ref-31-1">31</xref>).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp30" novelty="None" advantage="None"/></s>
        <s sid="80">All samples were scored by randomly selecting 20 fields of view and without knowledge of the treatment conditions.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp31" novelty="None" advantage="None"/></s>
        <s sid="81">Chi-squared analysis was performed to determine whether there was a significant difference in Ki67 staining between treatment conditions.<CoreSc1 atype="GSC" type="Met" conceptID="Met2" novelty="None" advantage="None"/></s>
        <s sid="82">Immunocytochemistry was repeated on seven independent MDA-MB-231 cultures.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp32" novelty="None" advantage="None"/></s>
      </p>
      <h3 xmlns:xhtml="http://www.w3.org/1999/xhtml">Protein isolation and western blot analysis of Cx43</h3>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-16">
        <s sid="83">Cells were rinsed once with PBS and then scraped off with lysis buffer [10% (v/v) glycerol (Fischer Scientific), 1% (v/v) Nonidet P-40 (Sigma-Aldrich), 0.1% (v/v) sodium dodecyl sulfate (SDS) (Fischer Scientific; Hampton, NH), 0.5 M NaCl, 5 mM Tris (pH 8.0) and protease inhibitor cocktail tablets (Complete, Mini; Roche, Indianapolis, IN)].<CoreSc1 atype="GSC" type="Exp" conceptID="Exp33" novelty="None" advantage="None"/></s>
        <s sid="84">DNA in the lysate was sheared using 22- and 27-gauge needles (Beckton Dickinson, Franklin Lakes, NJ).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp34" novelty="None" advantage="None"/></s>
        <s sid="85">Total protein concentrations were determined using the Bicinchoninic Acid (BCA) Protein Assay Kit (Pierce-BioLynx, Rockford, IL).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp35" novelty="None" advantage="None"/></s>
        <s sid="86">Western blot analysis was carried out in triplicate as we have described previously (<xref class="xref-bibr" href="#ref-32" rid="xref-ref-32-1">32</xref>).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp36" novelty="None" advantage="None"/></s>
      </p>
      <h3 xmlns:xhtml="http://www.w3.org/1999/xhtml">Measurement of gap junctional dye coupling</h3>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-17">
        <s sid="87">Using established protocols, the presence of functional gap junctional coupling was determined (<xref class="xref-bibr" href="#ref-33" rid="xref-ref-33-1">33</xref>).<CoreSc1 atype="GSC" type="Met" conceptID="Met3" novelty="None" advantage="None"/></s>
        <s sid="88">Cells were grown to confluence on 60 mm plates (two plates for each treatment condition; one donor plate and one recipient plate).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp37" novelty="None" advantage="None"/></s>
        <s sid="89">Following aspiration of treatment medium, donor cells were preloaded with dye solution [5 uM calcein-AM (Molecular Probes) and 10 &#956;M DiI (Sigma-Aldrich) in an isotonic (0.3 M) glucose solution] for 20 min in a humidified incubator (37&#176;C, 5% carbon dioxide/95% air).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp38" novelty="None" advantage="None"/></s>
        <s sid="90">Subsequently, the dye solution was aspirated from the donor plate, and the cells rinsed twice with glucose solution, trypsinized [0.25% trypsin (Invitrogen)] and suspended in 5 ml complete medium.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp39" novelty="None" advantage="None"/></s>
        <s sid="91">The donor cells were then seeded onto the recipient (unlabeled) cells at a 1:500 ratio.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp40" novelty="None" advantage="None"/></s>
        <s sid="92">Cells were maintained in the humidified incubator for 6 h and then examined using the aforementioned photomicroscope, capture software, and FITC and rhodamine filters (excitation 570 nm/emission 590 nm).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp41" novelty="None" advantage="None"/></s>
        <s sid="93">In addition, dye coupling was also assessed using the scrape loading method as described by Ozog et al. (<xref class="xref-bibr" href="#ref-32" rid="xref-ref-32-2">32</xref>).<CoreSc1 atype="GSC" type="Met" conceptID="Met4" novelty="None" advantage="None"/></s>
      </p>
      <h3 xmlns:xhtml="http://www.w3.org/1999/xhtml">Cell count</h3>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-18">
        <s sid="94">A total of 2.75 &#215; 10<sup>5</sup> MDA-MB-231 cells were seeded in triplicate at 10% confluence for each treatment condition (genistein or quercetin, complete medium only, or 0.1% (v/v) DMSO vehicle control).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp42" novelty="None" advantage="None"/></s>
        <s sid="95">Following 72 h treatment, the cells were trypsinized [trypsin&#8211;EDTA, Invitrogen] and suspended in 5 ml medium, and counted using the Beckman Coulter Counter (Beckman Coulter).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp43" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-19">
        <s sid="96">Data were analyzed using one-way analysis of variance (ANOVA).<CoreSc1 atype="GSC" type="Met" conceptID="Met5" novelty="None" advantage="None"/></s>
        <s sid="97">The treatment conditions were compared against the 0.1% (v/v) DMSO vehicle control using the Dunnett multiple comparisons test.<CoreSc1 atype="GSC" type="Met" conceptID="Met6" novelty="None" advantage="None"/></s>
      </p>
      <h3 xmlns:xhtml="http://www.w3.org/1999/xhtml">Cytotoxicity test</h3>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-20">
        <s sid="98">Lactate dehydrogenase (LDH) release was used as a measure of cytotoxicity.<CoreSc1 atype="GSC" type="Met" conceptID="Met7" novelty="None" advantage="None"/></s>
        <s sid="99">Released LDH in culture supernatants was measured with a 30 min coupled enzymatic assay using the CytoTox-96 Non-Radioactive Cytotoxicity Assay (Promega, Madison, WI).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp44" novelty="None" advantage="None"/></s>
        <s sid="100">The ratio of treatment-induced LDH to total cellular LDH was determined for each day of the 3 day treatment period.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp45" novelty="None" advantage="None"/></s>
        <s sid="101">Results were normalized to the 0.1% (v/v) DMSO vehicle condition.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp46" novelty="None" advantage="None"/></s>
        <s sid="102">Data were analyzed using one-way ANOVA.<CoreSc1 atype="GSC" type="Met" conceptID="Met8" novelty="None" advantage="None"/></s>
        <s sid="103">The treatment conditions were compared against the 0.1% (v/v) DMSO vehicle using the Dunnett multiple comparisons test.<CoreSc1 atype="GSC" type="Met" conceptID="Met9" novelty="None" advantage="None"/></s>
        <s sid="104">This cytotoxicity procedure was repeated on extracts from three different cultures for both MDA-MB-231 and MSTV1-7 cells.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp47" novelty="None" advantage="None"/></s>
      </p>
    </SEC>
    <SEC>
      <TITLE>Results</TITLE>
      <h3 xmlns:xhtml="http://www.w3.org/1999/xhtml">Effect of genistein and quercetin on Cx43 protein levels</h3>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-21">
        <s sid="105">MDA-MB-231 cells are a metastatic human breast tumor line, which express a very low level of Cx43 protein, and do not form functional gap junctions (<xref class="xref-bibr" href="#ref-17" rid="xref-ref-17-2">17</xref>).<CoreSc1 atype="GSC" type="Obj" conceptID="Obj5" novelty="None" advantage="None"/></s>
        <s sid="106">Western blot analysis was used to determine the relative amount of Cx43 produced following flavonoid treatment.<CoreSc1 atype="GSC" type="Goa" conceptID="Goa2" novelty="None" advantage="None"/><CoreSc2 atype="GSC" type="Met" conceptID="Met10" novelty="None" advantage="None"/></s>
        <s sid="107">Total protein loaded into each well was determined by probing with an antibody against GAPDH.<CoreSc1 atype="GSC" type="Met" conceptID="Met11" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-22">
        <s sid="108">Compared with the 0.1% (v/v) DMSO vehicle and complete medium only, Cx43 protein levels increased following genistein and quercetin treatment (<xref class="xref-fig" href="#F1" rid="xref-fig-1-1">Figure 1A and B</xref>).<CoreSc1 atype="GSC" type="Res" conceptID="Res6" novelty="None" advantage="None"/></s>
        <s sid="109">Interestingly, as seen in <xref class="xref-fig" href="#F1" rid="xref-fig-1-2">Figure 1A</xref>, treatment with physiological levels of genistein (0.5 &#956;g/ml) increased the level of Cx43.<CoreSc1 atype="GSC" type="Obs" conceptID="Obs3" novelty="None" advantage="None"/></s>
        <s sid="110">The amount of Cx43 increased further following 2.5 &#956;g/ml genistein treatment.<CoreSc1 atype="GSC" type="Obs" conceptID="Obs4" novelty="None" advantage="None"/></s>
        <s sid="111">However, higher genistein concentrations (up to 20 &#956;g/ml) did not raise Cx43 levels beyond that observed at 2.5 &#956;g/ml.<CoreSc1 atype="GSC" type="Obs" conceptID="Obs5" novelty="None" advantage="None"/></s>
        <s sid="112">Quercetin treatment, at concentrations of 2.5 and 5 &#956;g/ml, consistently increased Cx43 protein compared with the 0.1% (v/v) DMSO vehicle and complete medium only (<xref class="xref-fig" href="#F1" rid="xref-fig-1-3">Figure 1B</xref>).<CoreSc1 atype="GSC" type="Res" conceptID="Res7" novelty="None" advantage="None"/></s>
        <s sid="113">Interestingly, treatment with 15 &#956;g/ml quercetin did not upregulate Cx43 protein compared with the 0.1% DMSO vehicle and complete medium only.<CoreSc1 atype="GSC" type="Res" conceptID="Res8" novelty="None" advantage="None"/></s>
        <s sid="114">This was probably due to cytotoxic effects (see below).<CoreSc1 atype="GSC" type="Con" conceptID="Con2" novelty="None" advantage="None"/></s>
      </p>
      <h3 xmlns:xhtml="http://www.w3.org/1999/xhtml">Effects of genistein and quercetin on Cx43 localization</h3>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-24">
        <s sid="115">Immunocytochemistry was performed to determine intracellular localization of Cx43.<CoreSc1 atype="GSC" type="Goa" conceptID="Goa3" novelty="None" advantage="None"/><CoreSc2 atype="GSC" type="Met" conceptID="Met12" novelty="None" advantage="None"/></s>
        <s sid="116">Cx43 was localized to the plasma membrane in non-tumorigenic human breast cells (MSTV1-7) (<xref class="xref-fig" href="#F2" rid="xref-fig-2-1">Figure 2A</xref>).<CoreSc1 atype="GSC" type="Obs" conceptID="Obs6" novelty="None" advantage="None"/></s>
        <s sid="117">Compared with the DMSO treated cells (<xref class="xref-fig" href="#F2" rid="xref-fig-2-2">Figure 2B</xref>), treatment with 2.5 and 15 &#956;g/ml genistein resulted in an apparent increase in Cx43 protein (<xref class="xref-fig" href="#F2" rid="xref-fig-2-3">Figure 2D and E</xref>).<CoreSc1 atype="GSC" type="Res" conceptID="Res9" novelty="None" advantage="None"/></s>
        <s sid="118">Furthermore, some of the Cx43 appeared to localize as punctuate staining at the plasma membrane following genistein treatment.<CoreSc1 atype="GSC" type="Obs" conceptID="Obs7" novelty="None" advantage="None"/></s>
        <s sid="119">Quercetin treatment (0.5, 2.5, 5 &#956;g/ml) also produced more Cx43 protein compared with the untreated cells (<xref class="xref-fig" href="#F2" rid="xref-fig-2-4">Figure 2F</xref>).<CoreSc1 atype="GSC" type="Res" conceptID="Res10" novelty="None" advantage="None"/></s>
        <s sid="120">Interestingly, Cx43 protein did not appear localized to the plasma membrane following quercetin treatment.<CoreSc1 atype="GSC" type="Obs" conceptID="Obs8" novelty="None" advantage="None"/></s>
        <s sid="121">Instead, cells treated with quercetin appeared to retain Cx43 in the perinuclear region.<CoreSc1 atype="GSC" type="Obs" conceptID="Obs9" novelty="None" advantage="None"/></s>
        <s sid="122">Immunocytochemistry revealed that MDA-MB-231 cells are heterogeneous with respect to Cx43 expression after treatment (<xref class="xref-fig" href="#F2" rid="xref-fig-2-5">Figure 2D&#8211;F</xref>).<CoreSc1 atype="GSC" type="Res" conceptID="Res11" novelty="None" advantage="None"/></s>
      </p>
      <h3 xmlns:xhtml="http://www.w3.org/1999/xhtml">Effect of genistein and quercetin on GJIC</h3>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-26">
        <s sid="123">The effect of genistein and quercetin on GJIC was studied using both the scrape loading and preloading dye transfer techniques.<CoreSc1 atype="GSC" type="Met" conceptID="Met13" novelty="None" advantage="None"/></s>
        <s sid="124">HS578T cells are shown as a positive control for GJIC as measured by the preloading technique (<xref class="xref-fig" href="#F3" rid="xref-fig-3-1">Figure 3A&#8211;C</xref>).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp48" novelty="None" advantage="None"/></s>
        <s sid="125">In these cells, the gap junction-permeable dye, calcein, passed from the preloaded cells to many surrounding cells.<CoreSc1 atype="GSC" type="Obs" conceptID="Obs10" novelty="None" advantage="None"/></s>
        <s sid="126">Untreated MDA-MB-231 cells did not exhibit GJIC (data not shown).<CoreSc1 atype="GSC" type="Obs" conceptID="Obs11" novelty="None" advantage="None"/></s>
        <s sid="127">Genistein and quercetin treatment failed to increase GJIC in MDA-MB-231 cells (<xref class="xref-fig" href="#F3" rid="xref-fig-3-2">Figure 3D&#8211;F</xref>).<CoreSc1 atype="GSC" type="Obs" conceptID="Obs12" novelty="None" advantage="None"/></s>
        <s sid="128">Extra care was taken to observe preloaded cells in contact with surrounding cells because cell density was reduced following 72 h treatment with 15 &#956;g/ml genistein and 5 &#956;g/ml quercetin.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp49" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-28">
        <s sid="129">To test for a false negative result and to account for the observed heterogeneity in Cx43 expression in treated cells, GJIC was also measured by the scrape loading technique.<CoreSc1 atype="GSC" type="Goa" conceptID="Goa4" novelty="None" advantage="None"/><CoreSc2 atype="GSC" type="Met" conceptID="Met14" novelty="None" advantage="None"/></s>
        <s sid="130">The scrape loading results (<xref class="xref-fig" href="#F3" rid="xref-fig-3-3">Figure 3 G&#8211;J</xref>) confirmed the results obtained by the preloading technique.<CoreSc1 atype="GSC" type="Res" conceptID="Res12" novelty="None" advantage="None"/></s>
      </p>
      <h3 xmlns:xhtml="http://www.w3.org/1999/xhtml">Effect of genistein and quercetin on cell proliferation</h3>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-29">
        <s sid="131">Cell counts were performed to determine whether genistein and quercetin treatment suppressed growth of MDA-MB-231 cells (<xref class="xref-fig" href="#F4" rid="xref-fig-4-1">Figure 4</xref>).<CoreSc1 atype="GSC" type="Goa" conceptID="Goa5" novelty="None" advantage="None"/><CoreSc2 atype="GSC" type="Hyp" conceptID="Hyp2" novelty="None" advantage="None"/></s>
        <s sid="132">There was no significant difference in cell number between the complete medium only and the 0.1% (v/v) DMSO vehicle.<CoreSc1 atype="GSC" type="Res" conceptID="Res13" novelty="None" advantage="None"/></s>
        <s sid="133">Comparing flavonoid treated cells with the 0.1% (v/v) DMSO vehicle, 2.5 &#956;g/ml (P &lt; 0.05) and 15 &#956;g/ml (P &lt; 0.01) genistein, and 2.5 &#956;g/ml (P &lt; 0.05), 5 &#956;g/ml (P &lt; 0.01) and 15 &#956;g/ml (P &lt; 0.01) quercetin significantly reduced cell number.<CoreSc1 atype="GSC" type="Res" conceptID="Res14" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-31">
        <s sid="134">Cell proliferation was also measured by immunocytochemistry (<xref class="xref-fig" href="#F5" rid="xref-fig-5-1">Figure 5</xref>).<CoreSc1 atype="GSC" type="Met" conceptID="Met15" novelty="None" advantage="None"/></s>
        <s sid="135">Ki67 expression in MDA-MB-231 cells was examined following 72 h treatment with 15 &#956;g/ml genistein, 5 &#956;g/ml quercetin or 0.1% (v/v) DMSO vehicle.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp50" novelty="None" advantage="None"/></s>
        <s sid="136">All cells which received 0.1% (v/v) DMSO vehicle treatment expressed some level of Ki67, and therefore were dividing (<xref class="xref-fig" href="#F5" rid="xref-fig-5-2">Figure 5B</xref>; <xref class="xref-table" href="#T1" rid="xref-table-wrap-1-1">Table I</xref>).<CoreSc1 atype="GSC" type="Res" conceptID="Res15" novelty="None" advantage="None"/></s>
        <s sid="137">In contrast, only 44.4% of cells were immunoreactive for Ki67 following 5 &#956;g/ml quercetin treatment (<xref class="xref-fig" href="#F5" rid="xref-fig-5-3">Figure 5A</xref>; <xref class="xref-table" href="#T1" rid="xref-table-wrap-1-2">Table I</xref>).<CoreSc1 atype="GSC" type="Res" conceptID="Res16" novelty="None" advantage="None"/></s>
        <s sid="138">Approximately 73.8% of cells treated with 15 &#956;g/ml genistein were immunoreactive for Ki67 (<xref class="xref-table" href="#T1" rid="xref-table-wrap-1-3">Table I</xref>).<CoreSc1 atype="GSC" type="Res" conceptID="Res17" novelty="None" advantage="None"/></s>
        <s sid="139">These results support the cell count results: namely, genistein (P &lt; 0.0001) and quercetin (P &lt; 0.0001) reduce proliferation of MDA-MB-231 cells compared with control conditions.<CoreSc1 atype="GSC" type="Res" conceptID="Res18" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-34">
        <s sid="140">Cx43 staining was observed in conjunction with Ki67 and DAPI staining to determine whether genistein and quercetin-induced Cx43 contributed to reduced cell proliferation (<xref class="xref-fig" href="#F5" rid="xref-fig-5-4">Figure 5C and D</xref>).<CoreSc1 atype="GSC" type="Goa" conceptID="Goa6" novelty="None" advantage="None"/><CoreSc2 atype="GSC" type="Met" conceptID="Met16" novelty="None" advantage="None"/></s>
        <s sid="141">MDA-MB-231 cells, which expressed Cx43 following either 15 &#956;g/ml genistein or 5 &#956;g/ml quercetin treatment, did not show a difference in Ki67 immunoreactivity compared with cells that did not produce Cx43.<CoreSc1 atype="GSC" type="Res" conceptID="Res19" novelty="None" advantage="None"/></s>
      </p>
      <h3 xmlns:xhtml="http://www.w3.org/1999/xhtml">Cytotoxicity of genistein and quercetin</h3>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-35">
        <s sid="142">In order to determine whether the observed effects of proliferation might be due to cytotoxic effects of genistein and quercetin, we assessed LDH release during the time course of treatment.<CoreSc1 atype="GSC" type="Hyp" conceptID="Hyp3" novelty="None" advantage="None"/><CoreSc2 atype="GSC" type="Goa" conceptID="Goa7" novelty="None" advantage="None"/></s>
        <s sid="143">During the first 24 h of treatment, a significantly greater amount of LDH was released from MDA-MB-231 and MSTV1-7 cells treated with 15 &#956;g/ml quercetin compared with the 0.1% (v/v) DMSO vehicle, consistent with cytotoxicity at this higher dose (data not shown).<CoreSc1 atype="GSC" type="Res" conceptID="Res20" novelty="None" advantage="None"/></s>
        <s sid="144">No other treatment concentrations were toxic to MDA-MB-231 or MSTV1-7 cells during any period of the 72 h treatment duration (<xref class="xref-fig" href="#F6" rid="xref-fig-6-1">Figure 6</xref>).<CoreSc1 atype="GSC" type="Res" conceptID="Res21" novelty="None" advantage="None"/></s>
        <s sid="145">Therefore, the significant reduction in cell number cannot be attributed to genistein or quercetin toxicity.<CoreSc1 atype="GSC" type="Con" conceptID="Con3" novelty="None" advantage="None"/></s>
      </p>
    </SEC>
    <SEC>
      <TITLE>Discussion</TITLE>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-37">
        <s sid="146">Breast cancer is the second most frequent cause of death among North American women (<xref class="xref-bibr" href="#ref-34" rid="xref-ref-34-1">34</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac34" novelty="None" advantage="None"/></s>
        <s sid="147">There are effective treatments for this disease.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac35" novelty="None" advantage="None"/></s>
        <s sid="148">Many breast cancer therapies focus on inhibiting the ER in an attempt to control proliferation.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac36" novelty="None" advantage="None"/></s>
        <s sid="149">However, unfortunately, one-third of breast cancer patients lack ERs, and these patients respond very poorly to chemotherapy and endocrine therapy (<xref class="xref-bibr" href="#ref-35" rid="xref-ref-35-1">35</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac37" novelty="None" advantage="None"/></s>
        <s sid="150">Furthermore, many cancer therapies are burdened by significant physiological and psychological side effects.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac38" novelty="None" advantage="None"/></s>
        <s sid="151">For example, tamoxifen, an effective adjuvant therapy for ER-positive breast cancer patients, has been associated with increased risk of endometrial cancer and thromboembolic disorders (<xref class="xref-bibr" href="#ref-2" rid="xref-ref-2-2">2</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac39" novelty="None" advantage="None"/></s>
        <s sid="152">Chemotherapy is associated with physical side effects including immunosuppression, hair loss, nausea, fatigue, diarrhea, weight gain, constipation and mucositis as well as cognitive deficits (<xref class="xref-bibr" href="#ref-2" rid="xref-ref-2-3">2</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac40" novelty="None" advantage="None"/></s>
        <s sid="153">Therefore, more effective preventative and therapeutic strategies are needed to manage this disease.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac41" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-38">
        <s sid="154">Increased connexin expression and improved GJIC may represent a new, effective therapy for breast cancer.<CoreSc1 atype="GSC" type="Hyp" conceptID="Hyp4" novelty="None" advantage="None"/></s>
        <s sid="155">GJIC is important for growth regulation.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac42" novelty="None" advantage="None"/></s>
        <s sid="156">Dysfunctional GJIC has been associated with metastatic breast cancer (<xref class="xref-bibr" href="#ref-36" rid="xref-ref-36-1">36</xref>), cell heterogeneity and is one of the earliest alterations associated with malignant transformation (<xref class="xref-bibr" href="#ref-8" rid="xref-ref-8-2">8</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac43" novelty="None" advantage="None"/></s>
        <s sid="157">Additionally, experimental research shows that connexin proteins have antitumor functions independent of GJIC.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac44" novelty="None" advantage="None"/></s>
        <s sid="158">Connexin upregulation has been associated with improved response to chemotherapy agents such as etoposide, paditaxel and doxorubicin (<xref class="xref-bibr" href="#ref-37" rid="xref-ref-37-1">37</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac45" novelty="None" advantage="None"/></s>
        <s sid="159">Furthermore, human breast cancer cells transfected with Cx26 and Cx43 showed suppressed growth independent of GJIC.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac46" novelty="None" advantage="None"/></s>
        <s sid="160">It was hypothesized that the connexin proteins disrupted the interaction between fibroblast growth factor and its receptor, reducing mitogenic activity (<xref class="xref-bibr" href="#ref-17" rid="xref-ref-17-3">17</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac47" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-39">
        <s sid="161">Genistein and quercetin have been reported to induce apoptosis and halt the cell cycle in several types of tumors including breast, prostate, colon and lung (<xref class="xref-bibr" href="#ref-38" rid="xref-ref-38-1">38</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac48" novelty="None" advantage="None"/></s>
        <s sid="162">This study aimed to determine whether genistein and quercetin reduce proliferation of a metastatic breast tumor cell line (MDA-MB-231) through gap junctional mechanisms.<CoreSc1 atype="GSC" type="Goa" conceptID="Goa8" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-40">
        <s sid="163">Cx43 is the most common connexin protein in breast tissue (<xref class="xref-bibr" href="#ref-7" rid="xref-ref-7-2">7</xref>).<CoreSc1 atype="GSC" type="Obj" conceptID="Obj6" novelty="None" advantage="None"/></s>
        <s sid="164">An inverse relationship has been reported between the amount of Cx43 protein and tumor severity.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac49" novelty="None" advantage="None"/></s>
        <s sid="165">Most high grade and metastatically aggressive tumors have relatively low levels of Cx43 (<xref class="xref-bibr" href="#ref-8" rid="xref-ref-8-3">8</xref>,<xref class="xref-bibr" href="#ref-36" rid="xref-ref-36-2">36</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac50" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-41">
        <s sid="166">MDA-MB-231 cells are a highly metastatic human breast tumor cell line, which express very low levels of Cx43 protein.<CoreSc1 atype="GSC" type="Obj" conceptID="Obj7" novelty="None" advantage="None"/></s>
        <s sid="167">Our study showed that Cx43 expression was maximally stimulated following treatment with 2.5 &#956;g/ml genistein.<CoreSc1 atype="GSC" type="Obs" conceptID="Obs13" novelty="None" advantage="None"/></s>
        <s sid="168">Quercetin maximally stimulated Cx43 protein at 5 &#956;g/ml.<CoreSc1 atype="GSC" type="Obs" conceptID="Obs14" novelty="None" advantage="None"/></s>
        <s sid="169">Importantly, 0.5 &#956;g/ml genistein (0.26 &#956;M) increased Cx43 protein.<CoreSc1 atype="GSC" type="Obs" conceptID="Obs15" novelty="None" advantage="None"/></s>
        <s sid="170">This result is significant because it represents the average genistein plasma concentration (0.28 &#956;M) reported in Japanese men (<xref class="xref-bibr" href="#ref-39" rid="xref-ref-39-1">39</xref>).<CoreSc1 atype="GSC" type="Res" conceptID="Res22" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-42">
        <s sid="171">The breast cancer incidence among Asian females is 4&#8211;6 times lower than among North American females.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac51" novelty="None" advantage="None"/></s>
        <s sid="172">Asians consume a diet rich in genistein (<xref class="xref-bibr" href="#ref-20" rid="xref-ref-20-2">20</xref>) and migratory studies demonstrate that breast cancer incidence among Asians dramatically increases when they move to North America (<xref class="xref-bibr" href="#ref-19" rid="xref-ref-19-2">19</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac52" novelty="None" advantage="None"/></s>
        <s sid="173">Therefore, it is possible that the high consumption of genistein among Asians is in part responsible for their lower breast cancer incidence (<xref class="xref-bibr" href="#ref-18" rid="xref-ref-18-2">18</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac53" novelty="None" advantage="None"/></s>
        <s sid="174">Given the results of this study, it would be interesting to measure the Cx43 protein levels in this population.<CoreSc1 atype="GSC" type="Mot" conceptID="Mot2" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-43">
        <s sid="175">The mechanism by which genistein and quercetin elicit Cx43 upregulation requires further study.<CoreSc1 atype="GSC" type="Mot" conceptID="Mot3" novelty="None" advantage="None"/></s>
        <s sid="176">Both flavonoids can bind to ER-&#945; and ER-&#946;, translocate to the nucleus and affect gene transcription through estrogen response elements (<xref class="xref-bibr" href="#ref-40" rid="xref-ref-40-1">40</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac54" novelty="None" advantage="None"/></s>
        <s sid="177">There is evidence that flavonoids can increase Cx26 and Cx43 expression by this mechanism (<xref class="xref-bibr" href="#ref-41" rid="xref-ref-41-1">41</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac55" novelty="None" advantage="None"/></s>
        <s sid="178">However, MDA-MB-231 cells are ER-negative.<CoreSc1 atype="GSC" type="Obj" conceptID="Obj8" novelty="None" advantage="None"/></s>
        <s sid="179">Therefore, genistein and quercetin must be able to affect Cx43 expression by a mechanism independent of the ER.<CoreSc1 atype="GSC" type="Hyp" conceptID="Hyp5" novelty="None" advantage="None"/></s>
        <s sid="180">Genistein and quercetin are lipophilic molecules and are therefore able to diffuse through the plasma and nuclear membrane.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac56" novelty="None" advantage="None"/></s>
        <s sid="181">It is possible that once inside the cell, genistein and quercetin may activate proteins involved in Cx43 transcription or directly stimulate Cx43 promoter regions.<CoreSc1 atype="GSC" type="Con" conceptID="Con4" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-44">
        <s sid="182">Gap junction formation requires that connexin proteins be located at the plasma membrane.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac57" novelty="None" advantage="None"/></s>
        <s sid="183">Few studies have investigated Cx43 localization following flavonoid treatment.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac58" novelty="None" advantage="None"/></s>
        <s sid="184">Ale-Agha et al. (<xref class="xref-bibr" href="#ref-12" rid="xref-ref-12-2">12</xref>) demonstrated that 75 &#956;g/ml genistein counteracted the tumor promoter-induced internalization of Cx43 in rat liver epithelial cells.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac59" novelty="None" advantage="None"/></s>
        <s sid="185">Chaumontet et al. (<xref class="xref-bibr" href="#ref-14" rid="xref-ref-14-2">14</xref>) also used rat liver epithelial cells to show that Cx43 localized to cell&#8211;cell contact points following treatment with 7 &#956;g/ml apigenin and 10 &#956;g/ml tangeretin.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac60" novelty="None" advantage="None"/></s>
        <s sid="186">In our study, there was no evidence of plasma membrane-associated Cx43 in untreated MDA-MB-231 cells.<CoreSc1 atype="GSC" type="Obs" conceptID="Obs16" novelty="None" advantage="None"/></s>
        <s sid="187">However, following treatments with 2.5 and 15 &#956;g/ml genistein, punctuate Cx43 staining appeared at cell borders.<CoreSc1 atype="GSC" type="Obs" conceptID="Obs17" novelty="None" advantage="None"/></s>
        <s sid="188">In contrast, Cx43 appeared localized in the perinuclear region following quercetin treatment.<CoreSc1 atype="GSC" type="Obs" conceptID="Obs18" novelty="None" advantage="None"/></s>
        <s sid="189">While these treatments did result in the appearance of Cx43 protein, this was not observed throughout the entire culture, highlighting the heterogeneity of the response of these cells to genistein and quercetin.<CoreSc1 atype="GSC" type="Res" conceptID="Res23" novelty="None" advantage="None"/></s>
        <s sid="190">The absence of any increase in gap junctional coupling following flavonoid treatment is not surprising given the lack of Cx43 at the cell membrane.<CoreSc1 atype="GSC" type="Res" conceptID="Res24" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-45">
        <s sid="191">Tumor promoting agents such as TPA and DDT inhibit GJIC contributing to alterations in cell proliferation and transformation (<xref class="xref-bibr" href="#ref-11" rid="xref-ref-11-2">11</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac61" novelty="None" advantage="None"/></s>
        <s sid="192">Studies have shown the ability of flavonoids to counteract tumor promoter-induced reduction in GJIC.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac62" novelty="None" advantage="None"/></s>
        <s sid="193">(&#8722;)Epicatechin, a flavonoid found in cocoa and green tea, is able to maintain GJIC in the presence of TPA in rat liver epithelial cells (<xref class="xref-bibr" href="#ref-12" rid="xref-ref-12-3">12</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac63" novelty="None" advantage="None"/></s>
        <s sid="194">Sai et al. (<xref class="xref-bibr" href="#ref-13" rid="xref-ref-13-1">13</xref>) demonstrated that green tea protects against pentachlorophenol-induced inhibition of GJIC in mice.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac64" novelty="None" advantage="None"/></s>
        <s sid="195">Without using a tumor promoter in the current study, it was found that neither genistein nor quercetin enhanced GJIC in MDA-MB-231 cells.<CoreSc1 atype="GSC" type="Res" conceptID="Res25" novelty="None" advantage="None"/></s>
        <s sid="196">The finding that Cx43 was localized to the plasma membrane following genistein treatment suggests that there must be factors other than aberrant Cx43 localization, which impede GJIC in MDA-MB-231 cells.<CoreSc1 atype="GSC" type="Con" conceptID="Con5" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-46">
        <s sid="197">Cells must be held in close proximity to form functional gap junction pores.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac65" novelty="None" advantage="None"/></s>
        <s sid="198">E-cadherin is an important intercellular adhesion molecule and is considered to be the most promising candidate for cell&#8211;cell interaction during gap junction formation (<xref class="xref-bibr" href="#ref-42" rid="xref-ref-42-1">42</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac66" novelty="None" advantage="None"/></s>
        <s sid="199">Interestingly, MDA-MB-231 cells do not express E-cadherin.<CoreSc1 atype="GSC" type="Obj" conceptID="Obj9" novelty="None" advantage="None"/></s>
        <s sid="200">This may represent one explanation for the lack of GJIC in this cell line.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac67" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-47">
        <s sid="201">Studies have reported the ability of genistein and quercetin to halt the cell cycle, induce apoptosis, and thus regulate the cell population (<xref class="xref-bibr" href="#ref-24" rid="xref-ref-24-2">24</xref>&#8211;<xref class="xref-bibr" href="#ref-27" rid="xref-ref-27-2">27</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac68" novelty="None" advantage="None"/></s>
        <s sid="202">In this study, cell proliferation analysis showed that genistein and quercetin treatment reduced MDA-MB-231 cell number compared to control conditions.<CoreSc1 atype="GSC" type="Res" conceptID="Res26" novelty="None" advantage="None"/></s>
        <s sid="203">An aliquot of 15 &#956;g/ml genistein and 5 &#956;g/ml quercetin produced the greatest reductions in cell number independent of cytotoxicity.<CoreSc1 atype="GSC" type="Res" conceptID="Res27" novelty="None" advantage="None"/></s>
        <s sid="204">The same concentrations of genistein and quercetin also reduced cell number in a metastatic, &#8216;sarcoma-like&#8217; human breast cancer cell line called Hs578T (data not shown).<CoreSc1 atype="GSC" type="Res" conceptID="Res28" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-48">
        <s sid="205">Staining MDA-MB-231 cells with DAPI and the proliferative marker Ki67 showed that genistein and quercetin significantly reduced breast tumor cell proliferation.<CoreSc1 atype="GSC" type="Res" conceptID="Res29" novelty="None" advantage="None"/></s>
        <s sid="206">To observe whether or not flavonoid-induced Cx43 had an effect on proliferation, Cx43 was co-localized with DAPI and Ki67.<CoreSc1 atype="GSC" type="Goa" conceptID="Goa9" novelty="None" advantage="None"/></s>
        <s sid="207">We observed Cx43 staining in cells which were both positive or negative for Ki67, suggesting the lack of any correlation between the presence of these two proteins.<CoreSc1 atype="GSC" type="Res" conceptID="Res30" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-49">
        <s sid="208">Cytotoxicity assays were performed on flavonoid treated MDA-MB-231 cells and MSTV1-7 cells.<CoreSc1 atype="GSC" type="Met" conceptID="Met17" novelty="None" advantage="None"/></s>
        <s sid="209">It was found that quercetin was more cytotoxic than genistein.<CoreSc1 atype="GSC" type="Res" conceptID="Res31" novelty="None" advantage="None"/></s>
        <s sid="210">Over a 3 day treatment period, genistein (0.5, 2.5, 15 &#956;g/ml) was not toxic to either the non-tumorigenic MSTV1-7 cells or metastatic MDA-MB-231 cells.<CoreSc1 atype="GSC" type="Obs" conceptID="Obs19" novelty="None" advantage="None"/></s>
        <s sid="211">However, 15 &#956;g/ml quercetin consistently produced a toxic reaction in both these cell lines.<CoreSc1 atype="GSC" type="Obs" conceptID="Obs20" novelty="None" advantage="None"/></s>
        <s sid="212">Interestingly, 15 &#956;g/ml quercetin did not enhance Cx43 expression in MDA-MB-231 cells, suggesting that the toxic effects interfered with the transcription or translation of Cx43.<CoreSc1 atype="GSC" type="Res" conceptID="Res32" novelty="None" advantage="None"/></s>
        <s sid="213">Because of the estrogenic effect of genistein and quercetin, there is some concern regarding hormonal side effects.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac69" novelty="None" advantage="None"/></s>
        <s sid="214">Chromosome aberrations have been reported following treatment with very high concentrations of genistein (25 &#956;M) (<xref class="xref-bibr" href="#ref-43" rid="xref-ref-43-1">43</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac70" novelty="None" advantage="None"/></s>
        <s sid="215">However, in vivo studies have shown no short-term or long-term reproductive problems in humans (<xref class="xref-bibr" href="#ref-44" rid="xref-ref-44-1">44</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac71" novelty="None" advantage="None"/></s>
        <s sid="216">Although more in vivo studies are needed, genistein and quercetin suppressed cell growth at concentrations not toxic to non-tumorigenic breast cells, suggesting that these two flavonoids could be used therapeutically.<CoreSc1 atype="GSC" type="Mot" conceptID="Mot4" novelty="None" advantage="None"/><CoreSc2 atype="GSC" type="Con" conceptID="Con6" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-50">
        <s sid="217">The growth suppressive effects of genistein and quercetin have been previously established.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac72" novelty="None" advantage="None"/></s>
        <s sid="218">However, the antitumor effects of genistein and quercetin on ER-negative metastatic breast cells through gap junctional mechanisms has not previously been investigated.<CoreSc1 atype="GSC" type="Mot" conceptID="Mot5" novelty="None" advantage="None"/></s>
        <s sid="219">This study provides evidence that genistein and quercetin suppressed proliferation of MDA-MB-231 cells at concentrations which were not toxic to non-tumorigenic and metastatic human breast cells.<CoreSc1 atype="GSC" type="Con" conceptID="Con7" novelty="None" advantage="None"/></s>
        <s sid="220">The suppressed proliferation was independent of GJIC as demonstrated by dye transfer.<CoreSc1 atype="GSC" type="Con" conceptID="Con8" novelty="None" advantage="None"/></s>
        <s sid="221">Furthermore, based on the limited changes in Cx43 immunoreactivity observed in MDA-MB-231 cells following flavonoid treatment, the major effects on proliferation are likely not due to changes in Cx43 expression.<CoreSc1 atype="GSC" type="Con" conceptID="Con9" novelty="None" advantage="None"/></s>
      </p>
    </SEC>
    <SEC>
      <TITLE>Acknowledgments</TITLE>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-57">
        <s sid="222">This work was supported by a grant from the Cancer Research Society Inc. CMJC was supported by Postgraduate scholarship from the Natural Sciences and Engineering Research Council of Canada.</s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-58">
        <s sid="223">Conflict of Interest Statement: None declared.</s>
      </p>
    </SEC>
    <SEC>
      <TITLE>Footnotes</TITLE>
    </SEC>
    <SEC>
      <TITLE>References</TITLE>
    </SEC>
  </BODY>
</PAPER>